Change in second-hand smoke exposure after a lung and head and neck cancer diagnosis and subsequent patient smoking cessation.

Authors

Lawson Eng

Lawson Eng

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Lawson Eng , Devon Alton , Tom Yoannidis , Yuyao Song , Robin Milne , Samantha Sarabia , Zahra Merali , Steven Habbous , M Catherine Brown , Ashlee Vennettilli , Frances A. Shepherd , Natasha Leighl , Andrew J. Hope , Doris Howell , Jennifer M. Jones , Peter Selby , Wei Xu , David Paul Goldstein , Meredith Elana Giuliani , Geoffrey Liu

Organizations

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Wharton Head & Neck Program, Princess Margaret Cancer Centre, Toronto, ON, Canada, Ontario Cancer Institute, Toronto, ON, Canada, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Ontario Cancer Institute, Toronto, ON, Canada, Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, Centre for Addiction and Mental Health, Toronto, ON, Canada, Department of Biostatistic, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Center, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, ON, Canada, Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada

Research Funding

No funding sources reported

Background: Exposure to second-hand smoke (SHS) after a cancer diagnosis is associated with continued smoking in lung and head and neck (HN) cancer patients (PMID: 24419133, 23765604). We evaluated whether complete reduction/cessation of SHS exposure around and after a diagnosis of lung or HN cancer is associated with smoking cessation in the cancer patient. Methods: Lung and HN cancer patients from Princess Margaret Cancer Centre (2006-12) completed questionnaires at diagnosis and follow-up (median 2 years apart) that assessed smoking history and SHS exposures (cohort design). These cancers were chosen because these patients had the highest rates of smoking at the time of diagnosis. Multivariate logistic regression analysis evaluated the association of cessation of SHS exposure after a diagnosis of cancer with subsequent smoking cessation, adjusted for significant covariates. A cross-sectional study (2014) of 90 lung and HNC smoking patients assessed consistency in associations. Results: For the cohort, 261/731 lung and 145/450 HN cancer patients smoked at diagnosis; subsequent overall quit rates were 69% and 50% respectively. 91% of lung and 94% of HN cancer patients were exposed to SHS at diagnosis while only 40% (lung) and 62% (HN) were exposed at follow-up. Cessation of SHS exposure was associated with smoking cessation in lung (aOR = 4.76, 95% CI [2.56-9.09], P< 0.001), HN (aOR = 5.00 [1.61-14.29], P< 0.001), and in both cancers combined (aOR = 5.00 [3.03-8.33], P< 0.001). The cross-sectional study had a similar trend for cessation of SHS with smoking cessation, but a lower magnitude of association (OR = 2.73, P= 0.09). However, when asked directly, only 13% of patients quit smoking with another individual. Conclusions: Cessation of SHS exposure was a frequent occurrence around cancer patients. This cessation of SHS exposure is significantly associated with smoking cessation in lung and HN cancer patients. However, few patients quit smoking at the same time as their friends, family or household. Changing the environment around cancer survivors to reduce SHS exposure and encouraging households/friends to quit smoking may both improve cessation rates in cancer patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Patient and Survivor Care

Track

Patient and Survivor Care

Sub Track

Psychosocial and Communication Research

Citation

J Clin Oncol 33, 2015 (suppl; abstr 9556)

DOI

10.1200/jco.2015.33.15_suppl.9556

Abstract #

9556

Poster Bd #

215

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Quality Care Symposium

Opioid tapering and discontinuation for head and neck cancer (HNC) survivors.

First Author: Talya Salz

Abstract

2023 ASCO Quality Care Symposium

The role of primary care in opioid prescribing for head and neck cancer (HNC) survivors.

First Author: Talya Salz

First Author: Lawson Eng

First Author: Lawson Eng